info@hytanpeptides.com
Hytan Peptides — Peptide CDMORequest Project Quote
Technical guide

Peptide CDMO Change Control for Repeat Orders

Gloved quality reviewer comparing two peptide material containers beside a change record; conceptual image

A repeat peptide order is a repeat only if the agreed material, tests, packaging and intended use still match the approved project. A small change on a purchase order can alter what the manufacturer has to assess. Put the change in writing before treating the earlier batch as a precedent.

Changes that deserve a technical review

Buyers commonly reopen a peptide CDMO project for one of five reasons:

  • Identity: a revised sequence reference, terminal modification, salt form or concentration.
  • Acceptance: a new purity requirement, impurity limit, test method or reporting unit.
  • Presentation: a different vial, closure, fill description, package configuration or label text.
  • Scale and supply: a materially different forecast, order size or release schedule.
  • Market: a changed destination, application or document package.

Some changes are administrative. Others affect feasibility, testing, comparability or the quotation. The supplier can classify the impact only after seeing the requested change against the approved version of the specification.

Use a short change record

Identify the baseline

Reference the last approved specification and relevant order or batch identifier. State the old and proposed values in separate fields. “Same as last time, except for packaging” leaves too much room for interpretation if the previous order had multiple presentations.

Record the decision and its owner

For each proposed difference, agree who reviews it, what comparison or document update is needed, and when the revised scope becomes effective. Keep commercial approval separate from technical approval. The buyer may accept a revised price while the quality team still needs to approve new release criteria.

  1. Describe the change and its reason.
  2. Check identity, analytical scope, packaging, logistics and downstream use.
  3. Record the agreed assessment and any new deliverables.
  4. Issue a controlled specification or written amendment before execution.

Where ICH Q10 fits

ICH Q10 describes change management across the lifecycle of pharmaceutical products, including the use of knowledge and quality risk management. It is a reference for programmes that fall within its pharmaceutical scope. It does not automatically turn a cosmetic peptide, research material or every CDMO quotation into a regulated medicinal product. The customer’s intended use and destination market determine the applicable controls.

For a transferred or repeat programme, the process development team can review what changed from the prior scope. Send the old reference and proposed revision through the project enquiry; see our CDMO process for the decision stages.

FAQ

Does a repeat order need a new specification?

Not automatically. It needs a clear reference to the approved specification. Any material change should be assessed and the controlled document updated or amended when necessary.

Can the purchase order itself serve as change approval?

A purchase order records a commercial request. It may not capture technical impact, analytical acceptance or quality approval. Agree those responsibilities in the project documentation.

When should the supplier hear about a new destination market?

Before the quotation is finalised. Documentation, labels and suitability review may differ by market and intended use.

Primary references

← More guides